glp 1 inhibitors Glucagon-like peptide-1 Understanding GLP-1 Inhibitors: How They
Description
A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month
Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity
A dietitian breaks down the science behind the hype and how they really work.
Rotate placement daily to keep skin happy
Explore BPS Biosciences solutions for GLP-1R research in diabetes
